| Authors: |
Atienzar FA; UCB BioPharma SPRL, Chemin du Foriest, R9 Building, 1420 Braine-l'Alleud, Belgium., Blomme EA; AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA., Chen M; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration (FDA), Jefferson, AR 72079, USA., Hewitt P; Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany., Kenna JG; Drug Safety Consultant, Macclesfield, Cheshire SK11, UK., Labbe G; Sanofi, Bâtiment C. Bernard, 13 Quai Jules Guesdes, Zone B, BP14, 94403 Vitry-sur-Seine Cedex, France., Moulin F; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA., Pognan F; Novartis Pharma AG, Klybeckstrasse 141, 4057 Basel, Switzerland., Roth AB; Hoffmann La-Roche Inc., 4000 Basel, Switzerland., Suter-Dick L; School of Life Sciences, University of Applied Sciences Northwestern Switzerland, Gründenstrasse 40, 4132 Muttenz, Switzerland., Ukairo O; Ipsen Biosciences Inc., 650 E Kendall Street, Cambridge, MA 02142, USA., Weaver RJ; Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284 Suresnes Cedex, France., Will Y; Pfizer R&D, Drug Safety Research and Development, Eastern Point Road, Groton, CT 06340, USA., Dambach DM; Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. |
